The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Renier BrentjensDuring ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Renier J. Brentjens from Memorial Sloan Kettering Cancer Center, New York, US, about the latest advances in CAR T-cell therapy.
Renier J. Brentjens spoke of the use of chimeric antigen receptor molecules, and how these therapies are moving away from conventional chemotherapy. These therapies work well in patients with relapsed/refractory lymphoma, and especially for those patients with diffuse large B-cell lymphoma, with remission for these patients often being durable.
What are the latest advances in CAR T-cell therapy?